The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Use of EGF A61G polymorphism to predict overall survival in a phase III study of gemcitabine plus cetuximab versus gemcitabine in patients with locally advanced or metastatic pancreatic adenocarcinoma (SWOG 0205).
Melissa Janae Labonte
No relevant relationships to disclose
Bryan H. Goldman
No relevant relationships to disclose
Wu Zhang
No relevant relationships to disclose
C. D. Blanke
No relevant relationships to disclose
Philip Agop Philip
Consultant or Advisory Role - Bristol-Myers Squibb; Lilly; Sanofi
Honoraria - Genentech; Roche
Research Funding - Genentech; Lilly; Sanofi
Ralph Wong
No relevant relationships to disclose
Eileen Mary O'Reilly
No relevant relationships to disclose
Jacqueline K. Benedetti
No relevant relationships to disclose
Heinz-Josef Lenz
Consultant or Advisory Role - Bristol-Myers Squibb; Genentech
Honoraria - Bristol-Myers Squibb; Genentech
Research Funding - Genentech; ImClone Systems